Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on developing novel treatments for cancer and fibrosis, has appointed Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler, board-certified in both dermatology and psychiatry, brings a unique combination of expertise and leadership experience in healthcare. She has been a practicing dermatologist since 2005 and has served on the Board of Directors for Bausch Health since 2016. Dr. Wechsler is also an adjunct clinical professor of psychiatry at Weill Cornell Medical College.
Dr. Carl Goldfischer, Chair of the Board of Galecto, expressed enthusiasm for Dr. Wechsler's appointment, highlighting her experience in guiding companies through critical growth stages. Dr. Wechsler holds a B.S. in psychology from Duke University, an M.D. from Cornell University Medical College, and recently earned an M.B.A. from Columbia Business School in 2024.
Galecto, Inc. (NASDAQ: GLTO), una società biotecnologica in fase clinica focalizzata sullo sviluppo di nuovi trattamenti per il cancro e la fibrosi, ha nominato Dr. Amy Wechsler nel suo Consiglio di Amministrazione. La Dr. Wechsler, certificata dal consiglio in dermatologia e psichiatria, porta una combinazione unica di competenza ed esperienza di leadership nel settore sanitario. È una dermatologa praticante dal 2005 e fa parte del Consiglio di Amministrazione di Bausch Health dal 2016. La Dr. Wechsler è anche professoressa clinica straordinaria di psichiatria presso il Weill Cornell Medical College.
Il Dr. Carl Goldfischer, Presidente del Consiglio di Galecto, ha espresso entusiasmo per la nomina della Dr. Wechsler, sottolineando la sua esperienza nel guidare le aziende attraverso fasi critiche di crescita. La Dr. Wechsler ha conseguito una laurea in psicologia presso la Duke University, un M.D. presso il Cornell University Medical College e ha recentemente ottenuto un M.B.A. presso la Columbia Business School nel 2024.
Galecto, Inc. (NASDAQ: GLTO), una empresa de biotecnología en etapa clínica centrada en desarrollar nuevos tratamientos para el cáncer y la fibrosis, ha designado a la Dra. Amy Wechsler en su Junta Directiva. La Dra. Wechsler, certificada en dermatología y psiquiatría, aporta una combinación única de experiencia y liderazgo en el ámbito de la salud. Ha sido dermatóloga en ejercicio desde 2005 y ha formado parte de la Junta Directiva de Bausch Health desde 2016. La Dra. Wechsler también es profesora clínica adjunta de psiquiatría en el Weill Cornell Medical College.
El Dr. Carl Goldfischer, Presidente de la Junta de Galecto, expresó su entusiasmo por la designación de la Dra. Wechsler, destacando su experiencia en guiar a empresas a través de etapas críticas de crecimiento. La Dra. Wechsler tiene una licenciatura en psicología de la Duke University, un M.D. del Cornell University Medical College, y recientemente obtuvo un M.B.A. de la Columbia Business School en 2024.
Galecto, Inc. (NASDAQ: GLTO)는 암과 섬유증에 대한 새로운 치료법 개발에 초점을 맞춘 임상 단계의 생명공학 회사로 이사회에 앤디 웨흐슬러 박사를 임명했습니다. 웨흐슬러 박사는 피부과 및 정신의학 분야의 전문 자격을 보유하고 있으며, 의료 분야에서 독특한 전문성과 리더십 경험을 제공합니다. 그녀는 2005년부터 피부과 의사로 활동해왔으며, 2016년부터 Bausch Health의 이사회에서 활동하고 있습니다. 웨흐슬러 박사는 또한 Weill Cornell Medical College의 정신의학 임상 부교수로 재직 중입니다.
Galecto 이사회 의장인 칼 골드피셔 박사는 웨흐슬러 박사의 임명에 대한 기대감을 표명하며, 그녀의 기업 성장 단계에서의 경험을 강조했습니다. 웨흐슬러 박사는 듀크 대학교에서 심리학 학사학위를, Cornell University Medical College에서 의학 박사 학위를, 최근 2024년에는 컬럼비아 경영대학원에서 MBA를 취득했습니다.
Galecto, Inc. (NASDAQ: GLTO), une entreprise de biotechnologie en phase clinique axée sur le développement de nouveaux traitements pour le cancer et la fibrose, a nommé Dr. Amy Wechsler à son conseil d'administration. Dr. Wechsler, certifiée en dermatologie et psychiatrie, apporte une combinaison unique d'expertise et d'expérience en leadership dans le domaine de la santé. Elle est dermatologue en exercice depuis 2005 et siège au conseil d'administration de Bausch Health depuis 2016. Dr. Wechsler est également professeure clinique auxiliaire de psychiatrie au Weill Cornell Medical College.
Dr. Carl Goldfischer, président du conseil de Galecto, a exprimé son enthousiasme pour la nomination de Dr. Wechsler, soulignant son expérience dans l'accompagnement des entreprises à travers des phases critiques de croissance. Dr. Wechsler détient un B.S. en psychologie de la Duke University, un M.D. du Cornell University Medical College et a récemment obtenu un M.B.A. à la Columbia Business School en 2024.
Galecto, Inc. (NASDAQ: GLTO), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung neuartiger Behandlungen für Krebs und Fibrose konzentriert, hat Dr. Amy Wechsler in seinen Verwaltungsrat berufen. Dr. Wechsler, die über eine Facharztausbildung in Dermatologie und Psychiatrie verfügt, bringt eine einzigartige Kombination aus Fachwissen und Führungserfahrung im Gesundheitswesen mit. Sie praktiziert seit 2005 als Dermatologin und ist seit 2016 Mitglied des Verwaltungsrats von Bausch Health. Dr. Wechsler ist außerdem außerordentliche Professorin für Psychiatrie am Weill Cornell Medical College.
Dr. Carl Goldfischer, Vorsitzender des Vorstands von Galecto, äußerte seine Begeisterung über die Ernennung von Dr. Wechsler und hob ihre Erfahrung hervor, Unternehmen durch kritische Wachstumsphasen zu führen. Dr. Wechsler hat einen B.S. in Psychologie von der Duke University, einen M.D. vom Cornell University Medical College und hat kürzlich 2024 einen M.B.A. an der Columbia Business School erworben.
- Appointment of Dr. Amy Wechsler to the Board of Directors, bringing expertise in dermatology and psychiatry
- Dr. Wechsler's experience in guiding companies through critical growth stages
- Expansion of Galecto's oncology pipeline
- None.
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry.
“We are thrilled to welcome Dr. Wechsler to our Board of Directors,” said Dr. Carl Goldfischer, Chair of the Board of Galecto. “Amy is a distinguished physician who has board certification in both dermatology and psychiatry. Her experience guiding companies through critical growth stages make her an important addition to our team as we develop novel cancer and liver treatments. We look forward to her strategic insights and contributions.”
Dr. Wechsler is board-certified in both dermatology and psychiatry and has been a practicing dermatologist since 2005. Since 2016, she has served on the Board of Directors for Bausch Health where she played a key role in supporting the company through a successful IPO. Dr. Wechsler is also an adjunct clinical professor of psychiatry at Weill Cornell Medical College. She received a B.S. in psychology, magna cum laude, Phi Beta Kappa, from Duke University and earned her M.D., Alpha Omega Alpha, from Cornell University Medical College. Dr. Wechsler also received her M.B.A. from Columbia Business School in 2024.
Dr. Wechsler commented, “I am honored to join the Galecto Board at this exciting time in the Company’s evolution as they expand their oncology pipeline. I look forward to contributing to Galecto’s mission to develop novel cancer and liver disease treatments and to collaborating with the management team and fellow Board members."
About Galecto
Galecto is a clinical-stage biopharmaceutical company committed to realizing the promise of novel treatments for cancer and liver diseases. The Company’s pipeline consists of first-in-class small molecule drug candidates that target cancer and fibrosis signaling pathways, including (i) an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; (ii) an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and (iii) as recently announced, a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of AML, which Galecto acquired from Bridge Medicines. Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Galecto’s focus and plans for preclinical and clinical development of its product candidates and pipeline. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements, Galecto claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Galecto's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties related to the development of Galecto’s product candidates and their therapeutic potential, having adequate funds and their use, and those disclosed in Galecto’s filings with the Securities and Exchange Commission (SEC), including, but not limited to, Galecto’s Annual Report on Form 10-K, as filed with the SEC on March 8, 2024. These forward-looking statements represent Galecto's judgment as of the time of this release. Galecto disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
For more information, contact:
| Investors/US | Media/EU |
| Ashley R. Robinson arr@lifesciadvisors.com | Sandya von der Weid svonderweid@lifesciadvisors.com |
| +1 617 430 7577 | +41 78 680 0538 |
FAQ
Who is the new Board member appointed by Galecto (GLTO)?
What is Dr. Amy Wechsler's background and experience relevant to Galecto (GLTO)?
How does Dr. Wechsler's appointment align with Galecto's (GLTO) business focus?
When did Galecto (GLTO) announce the appointment of Dr. Amy Wechsler to its Board of Directors?
